Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23773217 | 1.00 | PDE2A (0.37) | PDE2AHSPA5TAAR1BACE1CA1 | |
| SCHEMBL18787325 | 0.92 | PDE2A (0.38) | PDE2AHSPA5TAAR1BACE1CA1 | |
| SCHEMBL26538075 | 0.88 | PDE2A (0.36) | PDE2AHSPA5TAAR1 | |
| SCHEMBL23773310 | 0.88 | PDE2A (0.36) | PDE2AHSPA5TAAR1 | |
| SCHEMBL23773047 | 0.81 | PDE2A (0.34) | PDE2AHSPA5 | |
| SCHEMBL23773175 | 0.81 | PDE2A (0.34) | PDE2AHSPA5 | |
| SCHEMBL26538322 | 0.81 | PDE2A (0.34) | PDE2AHSPA5 | |
| SCHEMBL23773309 | 0.80 | PDE2A (0.32) | PDE2A | |
| SCHEMBL26538233 | 0.80 | PDE2A (0.32) | PDE2A | |
| SCHEMBL23773180 | 0.78 | PDE2A (0.31) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787832-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787832-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | PNP, RNMT, SLC29A1 | PDE2A 491/4885HSPA5 4575/4885TAAR1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.